Scarica l'app Stockscreener
0.5786
1.47%
0.0084
Dopo l'orario di chiusura:
.57
-0.0086
-1.49%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CTXR Giù?
Forum
Previsione
Frazionamento azionario
Citius Pharmaceuticals Inc Borsa (CTXR) Ultime notizie
CTXR News | CITIUS PHARMACEUTICALS INC (NASDAQ:CTXR) - ChartMill
CTXR Stock Price, Quote & Chart - ChartMill
Citius Pharmaceuticals stock trades quietly as investors await next catalysts - AD HOC NEWS
CTXR: LYMPHIR’s launch gains momentum with strong early adoption and expanded sales force - TradingView
Citius Pharmaceuticals at Moody Capital conference: launch gains traction By Investing.com - Investing.com UK
Citius Pharmaceuticals at Moody Capital conference: launch gains traction - Investing.com
CTXR: LYMPHIR launch drives early revenue and creates an investment arbitrage opportunity - TradingView
Citius Pharmaceuticals stock stabilizes as investors look to next data catalysts - ad-hoc-news.de
CTXR Should I Buy - Intellectia AI
Citius Pharma CEO to speak at two New York conferences - Stock Titan
Citius Pharmaceuticals to Participate in September 2026 Investor Conferences - PR Newswire
Citius Pharmaceuticals Inc. Warrant (CTXRW) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Citius Pharmaceuticals Inc. Warrant (CTXRW) Key Financial Ratios – Valuation, Profitability & More - Value Research
TFIN-P Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Citius Pharmaceuticals Inc. (CTXR) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Citius Pharmaceuticals Inc. Warrant (CTXRW) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
CITIUS ONCOLOGY, INC. SEC Filing (Aug 26, 2026) - Stock Titan
Citius Pharmaceuticals Inc (CTXR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Citius (CTXR) Earnings Report: Reported EPS Misses Expectations in the Latest Reading; Price Reaction: Shares Move 0.07% Higher in the Current UpdateFinal Results - vinanet.vn
Citius Pharmaceuticals Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Nasdaq gives Citius (NASDAQ: CTXR) more time before $1 delisting risk - Stock Titan
H.C. Wainwright reiterates Citius Pharmaceuticals stock rating at buy By Investing.com - Investing.com South Africa
Citius (CTXR) Market-Day Review: Finishes 1.78% Higher at $0.57 in the Latest Session; Key Levels: the Near-Term Reference Band Stretches From $0.54 to $0.60 in the Available RecordWMA Signal - vinanet.vn
Citius Oncology shares tumble as Q3 revenue misses forecasts despite LYMPHIR launch momentum - Yahoo Finance
Citius Pharmaceuticals (NASDAQ:CTXR): What Does Today’s Clinical Focus Checkpoint Mean? - Kalkine Media
Citius Pharmaceuticals (NASDAQ:CTXR): What Does Today’s Program Priorities Checkpoint Mean? - Kalkine Media
Is Citius Pharmaceuticals (CTXR) Worth the Investment After Q3 E - GuruFocus
CTXR Q4 2025 Earnings: EPS Misses Estimates by 45.04% While Stock Gains 3.0%Analyst Earnings Estimate - vinanet.vn
Citius Pharmaceuticals (CTXR) Gains 3% to $0.76 as Buyers Defend SupportBull Pennant - dars.gov.et
Citius Pharmaceuticals Reports LYMPHIR Revenue Growth, Explores CAR-T Combination - The Clinical Trial Vanguard
Citius Pharma Reports First LYMPHIR Revenue of $7.1M in Nine Months - minichart.com.sg
Citius Oncology (CTOR) director Jonathan Peri files Form 3 showing no common shares - Stock Titan
Citius Pharma Q3 EPS beats estimate, sales miss by 72% - scanx.trade
Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update - The AI Journal
Citius Pharmaceuticals Reports Q3 2026 Financial Results and LYMPHIR Progress - Intellectia AI
CTXR: LYMPHIR's launch drove $7.1M revenue and 77% gross margin, offset by higher launch costs - TradingView
Citius Oncology (CTOR) grows LYMPHIR sales but posts $41M nine-month loss - Stock Titan
Citius Oncology, Inc. Announces Appointment of Jonathan Peri, Ph.D., J.D., as Independent Director, Effective August 10, 2026 - marketscreener.com
Citius Pharmaceuticals (CTXR) holders report 3.0M-share, 9.9% beneficial stake - Stock Titan
CTXR Q3'26 Earnings: EPS estimate is (0.36) USD - TradingView
Citius Oncology appoints independent director Peri to board of directors - ROI-NJ
People on the Move: Jonathan Peri, Ph.D., J.D., Joins Citius Oncology’s Board of Directors - BioBuzz
Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri - Morningstar
Citius Pharmaceuticals expands Citius Oncology board to nine with appointment of Jonathan Peri - Traders Union
Citius Oncology Adds Jonathan Peri to Board as LYMPHIR Commercialization Advances - citybiz
Citius Oncology appoints Jonathan Peri to board of directors - Investing.com
Citius Pharmaceuticals (CTXR) Edges Higher by 1.92%, Maintaining Position Above Key Support at $0.69TWAP Entry - vinanet.vn
BREAKING: THE PRINTING HAS STARTED! Robert De Niro (xWXxQcdGpe) - Mshale
CTXR Q4 2025 Earnings: Bigger-Than-Expected Loss Meets 6.23% Share RallyEarnings Sentiment Score - careplusvn.com
Citius Oncology of Cranford says commercial response to cancer treatment is strong - ROI-NJ
Citius Oncology reports strong LYMPHIR U.S. launch momentum - TipRanks
Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment - Morningstar
Citius Pharmaceuticals (CTXR) Advances 5.7% to $0.63; Key Resistance at $0.66 in FocusGamma Flip Level - vinanet.vn
Citius Pharmaceuticals (CTXR) Tumbles 9.81% to $0.57 as Biotech Stock Approaches Critical SupportTake Profit Levels - vinanet.vn
CTXR Q4 2025 Earnings: Wider-than-Expected Loss Met with Positive Stock ReactionOne-Time Gain Impact - vinanet.vn
Citius Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:CTXR - TradingView
Citius Pharmaceuticals Inc (CTXR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
CTXR|Citius Pharmaceuticals Inc|Price:0.579|Chg%:+0.009 - TradingKey
Citius Pharmaceuticals Inc (CTXR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
3.06%
2.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):